B

Bonus Biogroup Ltd
TASE:BONS

Watchlist Manager
Bonus Biogroup Ltd
TASE:BONS
Watchlist
Price: 9.9 ILS 1.02% Market Closed
Market Cap: 121.1m ILS
Have any thoughts about
Bonus Biogroup Ltd?
Write Note

Net Margin
Bonus Biogroup Ltd

0%
Current
0%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-29.2m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
IL
Bonus Biogroup Ltd
TASE:BONS
121.1m ILS N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.9B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.6B EUR
-14%
Country IL
Market Cap 121.1m ILS
Net Margin N/A
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 315.2B USD
Net Margin
9%
Country US
Market Cap 141.9B USD
Net Margin
13%
Country US
Market Cap 116.4B USD
Net Margin
0%
Country US
Market Cap 104.5B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.9B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 35.6B EUR
Net Margin
-14%
No Stocks Found

Bonus Biogroup Ltd
Glance View

Market Cap
121.1m ILS
Industry
Biotechnology

Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

BONS Intrinsic Value
0.41 ILS
Overvaluation 96%
Intrinsic Value
Price
B

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-29.2m
/
Revenue
0
What is the Net Margin of Bonus Biogroup Ltd?

Based on Bonus Biogroup Ltd's most recent financial statements, the company has Net Margin of 0%.